MedTech | 13 December 2024 | News
In a significant advancement in nano-photonics, scientists at the Jawaharlal Nehru Centre for Advanced Scienti...Read more
Opinion | 01 December 2024 | Views
Indian Lifesciences Industry Going Ahead in its Innovation Journey While Navigating Challenges
India is a major supplier of vaccines, with more than 50 per cent of the world’s vaccines coming from In...Read more
MedTech | 13 December 2024 | News
In a significant advancement in nano-photonics, scientists at the Jawaharlal Nehru Centre for Advanced Scienti...Read more
Start-ups | 11 December 2024 | News
Gurugram-based startup VitusCare, one of India’s fastest-growing dialysis care providers and a leading p...Read more
Supplier | 13 December 2024 | News
Qiagen has announced the launch of Ingenuity Pathway Analysis (IPA) Interpret, a new feature designed to simpl...Read more
People | 13 December 2024 | News
Heartnet appoints Indranil Das as Senior Advisor - Technology
Heartnet India, an IoT-based solution dedicated to enhancing cardiac healthcare delivery, has announced the ap...Read more
Academics | 13 December 2024 | News
DigiNerve unveils orthopedics MS Course to connect medical education with surgical precision
DigiNerve, an EdTech platform by Jaypee Brothers Medical Publishers, is revolutionizing Orthopedic medical edu...Read more
Text blogs | 01 December 2024 | Views
HIV Prevention Remains Elusive
On December 1, the world gathers every year to commemorate World AIDS Day, which serves as an important remind...Read more
BioPharma’s Transformative & Strategic OUTLOOK 2025
The Indian biopharma industry witnessed notable transformative developments and announcements, marked by innovation, regulatory advancements, and market expansion this year. From achieving global recognition in biosimilars to advancing biomanufacturing capabilities and precision therapeutics, the sector has solidified its role as a key player in the global pharmaceutical landscape. This progress underscores India’s strategic focus on leveraging its robust infrastructure, skilled talent pool, and government support to meet the evolving demands of the healthcare industry. Key developments in 2024 include an increase in biosimilar approvals, enhanced collaborations for biologics and vaccines, and a focus on potential investments in cutting-edge technologies like Artificial Intelligence (AI), continuous manufacturing, and automation through biofoundries. Looking ahead, the industry is well-positioned to align with emerging trends that are shaping the global biopharma landscape for 2025 and beyond. These include the growing emphasis on precision medicine, a shift towards sustainable biomanufacturing practices, and an increase in demand for advanced therapies such as cell and gene therapies. With over $200 billion worth of biologic patents set to expire by 2030, Indian companies are poised to play a pivotal role in driving the next wave of innovation and accessibility in biologics and biosimilars. Let’s explore further.
For Feedback, please email us at: communications@mmactiv.com